| On the 31 July 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,327 million and NAV per share was SEK 55.43. |
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
|
|
|
|
|
| | | | | |
| Product Development | | | | |
| Prokarium | 42% | 483 | 6.19 | 11.2% |
| Xspray Pharma | 18% | 300 | 3.85 | 6.9% |
| Empros Pharma | 79% | 204 | 2.62 | 4.7% |
| KAHR Medical | 31% | 202 | 2.59 | 4.7% |
| Atrogi | 34% | 154 | 1.97 | 3.6% |
| Microbiotica | 11% | 138 | 1.76 | 3.2% |
| Lipum | 57% | 135 | 1.73 | 3.1% |
| Geneos Therapeutics | 12% | 103 | 1.32 | 2.4% |
| Xintela | 56% | 102 | 1.30 | 2.4% |
| Mendus | 24% | 97 | 1.24 | 2.2% |
| Toleranzia | 58% | 68 | 0.87 | 1.6% |
| EpiEndo Pharmaceuticals | 9% | 58 | 0.74 | 1.3% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.2% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 42 | 0.53 | 1.0% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Vitara Biomedical | 5% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 60% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | | 2,312 | 29.62 | 53.4% |
| | | | |
|
| Commercial Growth | | | |
|
| NorthX Biologics | 92% | 189 | 2.42 | 4.4% |
| Symcel | 31% | 169 | 2.16 | 3.9% |
| Nanologica | 39% | 95 | 1.22 | 2.2% |
| A3P Biomedical | 8% | 75 | 0.96 | 1.7% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Provell Pharmaceuticals | 72% | 70 | 0.90 | 1.6% |
| Frontier Biosolutions | 2% | 19 | 0.25 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | | 707 | 9.06 | 16.3% |
| | | | |
|
| Limited Partnerships, total | | 83 | 1.06 | 1.9% |
| | | | |
|
| Assets related to portfolio companies | | 404 | 5.17 | 9.3% |
| Other assets and liabilities | | 821 | 10.52 | 19.0% |
| | | | |
|
| NAV | | 4,327 | 55.43 | 100.0% |
| | |
|
| |
* indirect shares in Provell Pharmaceuticals
| | | |
|